^
    20h
    Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=240 --> 8
    Enrollment closed • Enrollment change
    21h
    Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)" (clinicaltrials.gov)
    P2, N=63, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin
    1d
    Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis. (PubMed, J Oral Biol Craniofac Res)
    While STRING analysis does not confer great significance to prognosis, it accentuates SLC1A5 as a hub in amino acid metabolism and tumor progression pathways in HNSC. The overexpression of SLC1A5 is linked with unfavorable survival in HNSCC, highlighting its value to the metabolic reprogramming in HNSCC.
    Preclinical • Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    1d
    Single-cell Deciphering of the Progression Trajectories of the Tumor Ecosystem in Laryngeal Squamous Cell Carcinoma. (PubMed, Int J Biol Sci)
    Additionally, LSCC was uniquely enriched for a pro-tumor SPP1+ macrophage subset with low phagocytic activity and high angiogenic potential, linked to poor prognosis. Our findings uncover key mechanisms driving LSCC malignant progression, offer insights for early diagnosis and prognosis assessment, and highlight MIF as a promising therapeutic target.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • LAMP3 (Lysosomal Associated Membrane Protein 3) • POSTN (Periostin)
    3d
    Single-cell transcriptomic landscape highlights epithelial-fibroblast interactions and CD44-mediated malignant traits in laryngeal squamous cell carcinoma. (PubMed, NPJ Precis Oncol)
    Functional assays confirmed that CD44 knockdown in vitro reduced proliferation, migration, invasion, and in vivo tumorigenesis, supporting its role in metastasis. These findings reveal the dynamic remodeling of epithelial and fibroblast compartments in LSCC and identify CD44 as a key driver of metastasis through fibroblast-epithelial interactions.
    Journal
    |
    CAV1 (Caveolin 1) • ACTA2 (Actin Alpha 2 Smooth Muscle)
    3d
    CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosis. (PubMed, Transl Oncol)
    The combined assessment of CD3 density and PD-L1 expression outperforms either marker alone in predicting survival outcomes in surgically treated patients without immunotherapy. CD3high and PD-L1 CPS ≥ 1 identifies patients with favorable prognosis and response to standard-of-care treatment. Nonetheless, the potential relevance of these markers for guiding immunotherapy in other setting remains to be explored.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    3d
    Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition. (PubMed, Strahlenther Onkol)
    Natural killer cells showed only a limited contribution to the killing of HNSCC cells pretreated with RT or RT + DDRi. However, a subset of patients with head and neck tumors-such as those represented by the HSC4 model-might still benefit from combining RT with ATMi rather than ATRi to enhance NK cell-mediated tumor killing.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    Imfinzi (durvalumab) • berzosertib (M6620) • AZD0156 • monalizumab (IPH2201)
    4d
    NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer. (PubMed, JCI Insight)
    Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1, with broader implications in other squamous carcinomas with NOTCH1 mutations.
    Journal
    |
    NOTCH1 (Notch 1)
    5d
    NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P1, N=46, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2027 | Trial primary completion date: Jun 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • ipatasertib (RG7440)
    5d
    NimoBenSeq: Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial (clinicaltrials.gov)
    P2/3, N=386, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Andewei (benmelstobart) • TheraCIM (nimotuzumab)
    5d
    A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=213, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium